Travere Therapeutics TVTX
NASDAQ TVTX
$56.93 +0.08 (+0.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022)

Updated

Travere Therapeutics' Liabilities from Discontinued Operations came in at $64.2 million for Q4 2022.

Analysis

Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Travere Therapeutics 5.36 Bn 4.96 Bn 167.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 64.20 Mn
API Access

Travere Therapeutics Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=TVTX&period=max&api_key=YOUR_API_KEY